Evidence map›Paper›PMID 37995912›Full record

ArticleMucosal immunology2024

A pro-inflammatory gut mucosal cytokine response is associated with mild COVID-19 disease and superior induction of serum antibodies.

Dana Costigan, Joe Fenn, Sandi Yen, Nicholas Ilott, Samuel Bullers, Jessica Hale, William Greenhalf, Emily Conibear, Aleksandra Koycheva, Kieran Madon and 18 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mucosal immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 6 institutions in 2 countries.

Dana CostiganMRC Translational Immune Discovery Unit, Weatherall Institute of Molecular Medicine, University of Oxford, UK.
Joe FennNIHR HPRU in Respiratory Infections, Imperial College London, London, UK. Electronic address: jfenn@ic.ac.uk.
Sandi YenOxford Centre for Microbiome Studies, Kennedy Institute of Rheumatology, University of Oxford, UK.
Nicholas IlottOxford Centre for Microbiome Studies, Kennedy Institute of Rheumatology, University of Oxford, UK.
Samuel BullersOxford Centre for Microbiome Studies, Kennedy Institute of Rheumatology, University of Oxford, UK; Kennedy Institute of Rheumatology, University of Oxford, UK.
Jessica HaleInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
William GreenhalfInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Emily ConibearNIHR HPRU in Respiratory Infections, Imperial College London, London, UK.
Aleksandra KoychevaNIHR HPRU in Respiratory Infections, Imperial College London, London, UK.
Kieran MadonNIHR HPRU in Respiratory Infections, Imperial College London, London, UK.
Ishrat JahanSection of Virology, Department of Infectious Disease, Imperial College London, London, UK.
Ming HuangSection of Virology, Department of Infectious Disease, Imperial College London, London, UK.
Anjna BadhanSection of Virology, Department of Infectious Disease, Imperial College London, London, UK.
Eleanor ParkerSection of Virology, Department of Infectious Disease, Imperial College London, London, UK.
Carolina RosadasSection of Virology, Department of Infectious Disease, Imperial College London, London, UK.
Kelsey JonesKennedy Institute of Rheumatology, University of Oxford, UK.
Myra McClureSection of Virology, Department of Infectious Disease, Imperial College London, London, UK.
Richard TedderSection of Virology, Department of Infectious Disease, Imperial College London, London, UK.
Graham TaylorSection of Virology, Department of Infectious Disease, Imperial College London, London, UK.
Kenneth J BaillieRoslin Institute, University of Edinburgh, Easter Bush, Edinburgh, UK.
Malcolm G SempleNIHR Health Protection Research Unit, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
Peter J M OpenshawNIHR HPRU in Respiratory Infections, Imperial College London, London, UK; National Heart and Lung Institute, Imperial College London, London, UK.
Claire PearsonOxford Centre for Microbiome Studies, Kennedy Institute of Rheumatology, University of Oxford, UK; Kennedy Institute of Rheumatology, University of Oxford, UK.
Jethro JohnsonOxford Centre for Microbiome Studies, Kennedy Institute of Rheumatology, University of Oxford, UK.
INSTINCT Study Group
ISARIC4C investigators
Ajit LalvaniNIHR HPRU in Respiratory Infections, Imperial College London, London, UK.
Emily E ThorntonMRC Translational Immune Discovery Unit, Weatherall Institute of Molecular Medicine, University of Oxford, UK; Nuffield Department of Medicine, University of Oxford, UK. Electronic address: emily.thornton@imm.ox.ac.uk.
Imperial College London · GBUniversity of Oxford · GBNIHR Imperial Biomedical Research Centre · GBUniversity of Liverpool · GBLung Institute · USRoslin Institute · GB

Funding

Medical Research Council MC_PC_19059Medical Research Council MC_UU_00008/6Medical Research Council MR/X004058/1
6 · The paper itself

Abstract

The relationship between gastrointestinal tract infection, the host immune response, and the clinical outcome of disease is not well understood in COVID-19. We sought to understand the effect of intestinal immune responses to SARS-CoV-2 on patient outcomes including the magnitude of systemic antibody induction. Combining two prospective cohort studies, International Severe Acute Respiratory and emerging Infections Consortium Comprehensive Clinical Characterisations Collaboration (ISARIC4C) and Integrated Network for Surveillance, Trials and Investigations into COVID-19 Transmission (INSTINCT), we acquired samples from 88 COVID-19 cases representing the full spectrum of disease severity and analysed viral RNA and host gut cytokine responses in the context of clinical and virological outcome measures. There was no correlation between the upper respiratory tract and faecal viral loads. Using hierarchical clustering, we identified a group of fecal cytokines including Interleukin-17A, Granulocyte macrophage colony-stimulating factor, Tumor necrosis factorα, Interleukin-23, and S100A8, that were transiently elevated in mild cases and also correlated with the magnitude of systemic anti-Spike-receptor-binding domain antibody induction. Receiver operating characteristic curve analysis showed that expression of these gut cytokines at study enrolment in hospitalised COVID-19 cases was associated negatively with overall clinical severity implicating a protective role in COVID-19. This suggests that a productive intestinal immune response may be beneficial in the response to a respiratory pathogen and a biomarker of a successful barrier response.

Indexed as

COVID-19Antibodies, ViralCytokinesFecesHumansProspective StudiesSARS-CoV-2Antibodies, ViralCytokines

Identifiers

PMID37995912
PMCPMC10884467
OpenAlexW4388905462

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.